浏览全部资源
扫码关注微信
1.石家庄市中医院郭光业传承工作室,石家庄 050051
2.石家庄市中医院检验科,石家庄 050051
王立业,男,40岁,硕士,副主任医师。研究方向:消化系统疾病的中医药诊疗。
收稿日期:2023-12-12,
纸质出版日期:2025-05-25
移动端阅览
王立业,张艳彬,朱亚楠,等.益胃解毒方联合复胃散胶囊治疗脾胃虚弱型幽门螺杆菌阳性胃癌前病变临床观察[J].北京中医药,2025,44(5):566-570.
WANG Liye,ZHANG Yanbin,ZHU Yanan,et al.Clinical observation of Yiwei Jiedu Formula combined with Fuweisan Capsules in the treatment of Helicobacter pylori-positive gastric precancerous lesions with spleen and stomach deficiency syndrome[J]. Beijing Journal of Traditional Chinese Medicine,2025,44(05):566-570.
王立业,张艳彬,朱亚楠,等.益胃解毒方联合复胃散胶囊治疗脾胃虚弱型幽门螺杆菌阳性胃癌前病变临床观察[J].北京中医药,2025,44(5):566-570. DOI: 10.16025/j.1674-1307.2025.05.006.
WANG Liye,ZHANG Yanbin,ZHU Yanan,et al.Clinical observation of Yiwei Jiedu Formula combined with Fuweisan Capsules in the treatment of Helicobacter pylori-positive gastric precancerous lesions with spleen and stomach deficiency syndrome[J]. Beijing Journal of Traditional Chinese Medicine,2025,44(05):566-570. DOI: 10.16025/j.1674-1307.2025.05.006.
目的
2
观察益胃解毒方联合复胃散胶囊治疗脾胃虚弱型幽门螺杆菌(Hp)阳性胃癌前病变的临床疗效。
方法
2
选取2019年6月—2022年6月石家庄市中医院收治的150例脾胃虚弱型Hp阳性胃癌前病变患者,采用随机数字表法分为3组,各50例。对照A组以益胃解毒方治疗,对照B组以复胃散胶囊治疗,观察组以益胃解毒方联合复胃散胶囊治疗,3组均以4周为1个疗程,连续治疗3个疗程。观察3组治疗前后胃黏膜病理状态(胃黏膜萎缩、上皮化生、异型增生、炎症活动度情况)评分、胃功能指标[胃蛋白酶原I(PG Ⅰ)、PG Ⅱ、胃泌素-17(G-17)]、可易位基因C(C-myc)、原癌基因(c-erbB-2)、炎症因子[热休克蛋白70(HSP70)、白细胞介素10(IL-10)、血清淀粉样蛋白A(SAA)],并比较临床疗效。
结果
2
观察组总有效率高于对照A组、对照B组(
P
<
0.05)。治疗后,观察组胃黏膜病理状态评分均低于对照A组、对照B组(
P
<
0.05),胃功能指标(PG Ⅰ、PG Ⅱ、G-17)、C-myc、c-erbB-2及炎症因子(HSP70、IL-10、SAA)水平均低于对照A组、对照B组(
P
<
0.05)。治疗期间观察组、对照A组、对照B组不良反应发生率比较,差异无统计学意义(
P
>
0.05)。
结论
2
益胃解毒方联合复胃散胶囊治疗Hp阳性胃癌前病变可有效改善胃黏膜病理变化及胃功能,抑制C-myc、c-erbB-2及炎症因子表达,临床有效且安全性良好。
Objective
2
To observe the clinical efficacy of
Yiwei Jiedu Formula
combined with
Fuweisan Capsules
in treating Helicobacter pylori (Hp)-positive gastric precancerous lesions with spleen and stomach deficiency syndrome.
Methods
2
A total of 150 patients with Hp-positive gastric precancerous lesions admitted to Shijiazhuang Hospital of Traditional Chinese Medicine from June 2019 to June 2022 were enrolled and randomly divided into three groups using a random number table method, with 50 cases in each group. Control group A was treated with
Yiwei Jiedu Formula
, control group B was treated with
Fuweisan Capsules
, and the observation group received
Yiwei Jiedu Formula
combined with
Fuweisan Capsules
. Each group was treated continuously for three courses, with each course lasting four weeks. Gastroscopic pathological scores (including gastric mucosal atrophy, intestinal metaplasia, dysplasia, and inflammatory activity), gastric function indicators [pepsinog
en I (PG I), pepsinogen II (PG II), gastrin-17 (G-17)], expression levels of translocation gene C (C-myc), proto-oncogene (c-erbB-2), and inflammatory factors [heat shock protein 70 (HSP70), interleukin-10 (IL-10), serum amyloid A (SAA)] were observed before and after treatment, along with clinical efficacy comparison.
Results
2
The total effective rate in the observation group was higher than that in control group A and control group B (
P
<
0.05). After treatment, gastroscopic pathological scores in the observation group were lower than those in the two control groups (
P
<
0.05). Gastric function indicators (PG I, PG II, G-17), C-myc, c-erbB-2, and inflammatory factors (HSP70, IL-10, SAA) were also significantly lower in the observation group compared with the control groups (
P
<
0.05). There was no significant difference in the incidence of adverse reactions among the observation group, control group A, and control group B during treatment (
P
>
0.05).
Conclusion
2
Yiwei Jiedu Formula
combined with
Fuweisan Capsules
effectively improves gastric mucosal pathological changes and gastric function, inhibits the expression of C-myc, c-erbB-2, and inflammatory factors, and is clinically effective with good safety in the treatment of Hp-positive gastric precancerous lesions.
张亮亮 , 李根 , 杨帅 , 等 . 网络药理学联合基因表达数据库芯片分析及分子对接技术探讨健脾清化化瘀汤治疗胃癌前病变的潜在机制 [J ] . 北京中医药 , 2023 , 42 ( 5 ): 501 - 507 .
SALVO CD , PIZARRO TT . IL-33 and eosinophils link inflammation and metaplasia in a mouse model of chronic gastritis with intestinalizing features [J ] . Gastroenterology , 2021 , 29 ( 12 ): 2772 - 2776 .
叶苏漫 , 叶晖 , 史宗明 , 等 . 基于VOSviewer,CiteSpace知识图谱的中医药与中西医结合治疗幽门螺杆菌的可视化分析 [J ] . 北京中医药 , 2023 , 42 ( 1 ): 98 - 105 .
张涛 , 苏晓兰 , 张涛 , 等 . 气滞胃痛颗粒联合标准四联治疗Hp阳性慢性胃炎患者的临床效果分析 [J ] . 中国中西医结合消化杂志 , 2021 , 29 ( 8 ): 284 - 288 .
谢晓妹 , 冉静纯 , 赵唯含 , 等 . 基于“虚瘀毒”理论的中医药治疗慢性萎缩性胃炎的Meta分析 [J ] . 中华中医药学刊 , 2020 , 38 ( 2 ): 108 - 114 .
张芳姣 , 吴雄鹰 , 张瑜平 . 温中健脾养胃汤治疗脾胃虚寒型慢性萎缩性胃炎的临床观察 [J ] . 中国中医药科技 , 2020 , 27 ( 3 ): 486 - 487 .
中华医学会消化病学分会 . 中国慢性胃炎共识意见(2017年,上海) [J ] . 中华消化杂志 , 2017 , 37 ( 11 ): 721 - 738 .
李军祥 , 陈誩 , 胡玲 , 等 . 慢性非萎缩性胃炎中西医结合诊疗共识意见(2017年) [J ] . 中国中西医结合消化杂志 , 2018 , 26 ( 1 ): 1 - 8 .
王洁 , 张云清 , 赵斌 , 等 . K-ras诱导细胞衰老与胃癌及癌前病变关系研究 [J ] . 陕西医学杂志 , 2021 , 50 ( 3 ): 370 - 373 .
KIM DH , SON BK , MIN KW , et al . Chronic gastritis is associated with a decreased high-density lipid level: histological features of gastritis based on the updated sydney system [J ] . J Clin Med , 2020 , 9 ( 6 ): 1856 - 1863 .
李亚可 , 方俐晖 , 张轶斐 , 等 . 从“因热生毒”探讨慢性萎缩性胃炎炎癌转化机制 [J ] . 北京中医药 , 2022 , 41 ( 3 ): 285 - 289 .
刘伟 , 杨良俊 , 袁冬生 , 等 . 基于网络药理学的黄芪-丹参药对治疗胃癌前病变作用机制 [J ] . 中华中医药杂志 , 2020 , 35 ( 1 ): 419 - 423 .
许亚培 , 李博林 , 徐伟超 , 等 . 益胃化浊解毒方联合维酶素片治疗慢性萎缩性胃炎胃癌前病变疗效及对Ki-67蛋白表达的影响 [J ] . 现代中西医结合杂志 , 2021 , 30 ( 36 ): 4018 - 4022 .
曾韦苹 , 张军汉 , 罗玉 . 半夏泻心汤加减联合三联疗法对消化性溃疡患者幽门螺杆菌的根治效果观察 [J ] . 北京中医药 , 2020 , 39 ( 9 ): 992 - 994 .
赵化成 , 洪焰 , 曾福生 , 等 . 胃癌前病变中医证型与Hp感染,胃黏膜病理改变相关性研究 [J ] . 实用中西医结合临床 , 2021 , 21 ( 15 ): 3 - 5 .
杨嘉欣 , 程志强 . 基于真实世界健脾益胃方联合SOX方案治疗胃癌根治术后患者的回顾性队列研究 [J ] . 中华中医药杂志 , 2022 , 37 ( 6 ): 3632 - 3635 .
LI Q , LI L . The diagnostic value of combined detection of genetic markers and serum protein markers on breast cancer [J ] . Saudi J Biol Sci , 2019 , 26 ( 1 ): 182 - 189 .
0
浏览量
1
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构